Scientists from the Tokyo University of Science and the University of Tsukuba have developed a new antidepressant medication with only a few side effects and works fast.
The KNT-127
Delta Opioid Receptors (DOPs) are important for the emergence of depression and related conditions. Therefore, they have been identified by researchers as possible antidepressant medications with fewer side effects and more efficacy compared to the ones available today.
KNT-127 is a selective DOP agonist, which the researchers evaluated. The researchers tested it on mice, which were subjected to high psychological stress for ten days, as reported by Interesting Engineering.
The KNT-127 was given during and after the stressful time to better evaluate its effectiveness. Researchers discovered that long-term administration of the antidepressant before, during, and after a stressful time enhanced social behavior and serum levels of corticosterone that the mice secrete during stress.
Stress-induced newborn neuronal death in the hippocampus was also observed to be reduced by the treatment. However, the neurogenesis was unaffected.
When given the following stress, the treatment didn't show an impact on the survival rates of neonatal neurons. It also inhibited microglial activation, which helped decrease inflammation in the hippocampus.
Read also: Anti-Inflammatory Drugs Could Help Treat Depression, But Do The Risks Outweigh The Benefits?
Dual-Nature
The study showed that KNT-127 has dual nature as it functions as a stress reliever and an antidepressant. Its anti-stress and antidepressant-like effects during and after stressful periods for by preventing neuronal inflammation and lowering neonatal neuronal mortality without affecting neuron development.
This opens up possibilities for the creation of new and better remedies for depression that are free from side effects. It can also offer additional benefits for patients at the time of treatment.
Fighting Depression Today
Depression is a serious mental health condition that affects millions of people worldwide. At the same time, there are many treatments available, including therapy and medication, but not all patients respond well to these options. That's why the discovery of KNT-127's dual nature is so exciting.
By targeting both stress and depression, KNT-127 could offer a new approach to treating these conditions. Its ability to prevent neuronal inflammation and lower neonatal neuronal mortality without affecting neuron development means that it may be able to provide relief without the side effects that often come with traditional antidepressants.
As research continues into KNT-127 and its potential applications, it's clear that the future of depression treatment is looking brighter than ever before. With new, innovative solutions on the horizon, we can hope to see more patients finding the help they need to overcome this debilitating condition and lead happier, healthier lives.
